Sangamo's Phase 2b trial did not meet key study endpoints Print E-mail
By Staff and Wire Reports   
Monday, 03 October 2011 08:20
fda calendarShares of Sangamo BioSciences (Nasdaq: SGMO) plunged in premarket trading Monday after the company said its most advanced drug candidate, a treatment for diabetic nerve pain, did not meet any of its goals in a mid-stage clinical trial.

Sangamo said it is ending development of SB-509, which was being studied as a treatment for diabetic neuropathy. The company said the drug worked about as well as it has in previous studies, but it was not significantly more effective than a placebo. It said patients who were treated with the placebo did better than expected on measurements including nerve conduction speed and impairment scores.

"We are disappointed that this trial did not produce a better outcome in the pre-specified primary and secondary endpoints," said Edward Lanphier, Sangamo's president and CEO. "Based on these results, we will discontinue further development of SB-509 and will focus our attention and resources on our pipeline of ZFP Therapeutics for HIV and monogenic diseases for which our genome editing technology is uniquely well positioned. We would like to thank the patients, investigators and the Juvenile Diabetes Research Foundation (JDRF) for their support and participation in the trial."

Shares of Sangamo sank $1.55, or 35.6 percent, to $2.80 in premarket trading.

The company develops drug candidates based on its zinc finger protein technology, which is aimed at turning off parts of genes. It is also studying drugs that could treat HIV, brain cancer, hemophilia, and other diseases. Sangamo said it will present full results from the 170-patient trial at a future medical conference.

Shares of Sangamo BioSciences have traded between $3.30 and $9.15 in the last year and closed at $4.35 Friday.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus